α4CB-1.1 / Trigone Pharma, 4C Biomed - LARVOL DELTA

Trigone Pharma Announces a Strategic Collaboration with 4C Biomed to Develop a Novel Treatment for High-Grade Bladder Cancer (GlobeNewswire) - "Trigone Pharma...announced a collaboration with 4C Biomed, to develop an innovative treatment for bladder cancer. The collaboration will focus on local administration of 4C Biomed’s anti 4CB-1 as an innovative treatment for high-grade non-muscle invasive bladder cancer....The approach involves the local delivery of 4C Biomed’s first-in-class monoclonal antibody that targets HVEM (TNFRSF14) - a novel Immunotherapy, using Trigone’s proprietary technology to increase dwell time - which has been shown to significantly improve the effectiveness of bladder targeted therapies."

Licensing / partnership • Bladder Cancer • Genito-urinary Cancer • Oncology • Urothelial Cancer